Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular...

Area of Science:

• Oncology
• Hematology
• Medical Imaging

Background:

• Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma.
• Standard first-line treatment involves immunochemotherapy.
• Accurate prognostication is crucial for managing high tumor burden FL.

Purpose of the Study:

• To evaluate the predictive value of total metabolic tumor volume (TMTV) and beta-2-microglobulin (B2M) levels.
• To assess the combined TMTV/B2M score's ability to predict outcomes in FL patients with high tumor burden.
• To identify patients with high unmet medical needs receiving standard therapy.

Main Methods:

• Retrospective analysis of 125 FL patients with high tumor burden.
• Patients received standard first-line immunochemotherapy (R-CHOP-like).
• TMTV and B2M levels were measured; risk categories (low, intermediate, high) were defined based on TMTV and B2M thresholds.

Main Results:

• Five-year overall survival rates were 96.1% (low-risk), 89.1% (intermediate-risk), and 73.7% (high-risk) (p=0.003).
• Intermediate-risk (TMTV > 510 cm³ or B2M > 3 mg/L) and high-risk (TMTV > 510 cm³ and B2M > 3 mg/L) patients had significantly higher risk of progression within 24 months.
• Hazard ratios for progression were 2.45 (intermediate) and 3.75 (high-risk).

Conclusions:

• The combined TMTV/B2M score is a significant predictor of survival and progression in high tumor burden FL.
• This score can identify FL patients at high risk of disease progression.
• The TMTV/B2M score may help stratify patients with the highest unmet medical needs for intensified treatment strategies.